David D. Meek
CIK: 0001555337
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 16, 2026CGEM
Cullinan Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
25.3K shares- - Jun 11, 2026QURE
uniQure N.V.
Sale(S)Direct2K shares at avg. $27.06$54K - Jun 10, 2026QURE
uniQure N.V.
Award(A)Direct7.6K shares- - Jun 20, 2025QURE
uniQure N.V.
Sale(S)Direct2.1K shares at avg. $14.45$31K - Jun 12, 2025CGEM
Cullinan Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
38.5K shares- - Jun 11, 2025QURE
uniQure N.V.
Award(A)Direct8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  CGEM Cullinan Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 25,319 | - | - | Direct |
| Jun 11, 2026 |  QURE uniQure N.V. | Sale(S) | 1,993 | $27.06 | $53,931 | Direct |
| Jun 10, 2026 | QURE uniQure N.V. | Award(A) | 7,550 | - | $0 | Direct |
| Jun 20, 2025 | QURE uniQure N.V. | Sale(S) | 2,112 | $14.45 | $30,518 | Direct |
| Jun 12, 2025 | CGEM Cullinan Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 38,513 | - | - | Direct |
| Jun 11, 2025 | QURE uniQure N.V. | Award(A) | 7,970 | - | - | Direct |
1-6 of 6 transactions
About Meek David D.
Meek David D. (SEC CIK 0001555337) files insider reports with the SEC as Director of Cullinan Therapeutics, Inc. (CGEM) and Director of uniQure N.V. (QURE).
Signal8 holds 5 ownership filings by Meek David D., all Form 4s, filed between Jun 13, 2025 and Jun 18, 2026. Those filings report 6 transactions, from Jun 11, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Meek David D.'s filings is in AMSTERDAM.
Recent filings by Meek David D.
- Jun 16, 2026: Grant or award of CGEM derivative securities (Form 4, code A).
- Jun 11, 2026: Open-market sale of QURE shares (Form 4, code S).
- Jun 10, 2026: Grant or award of QURE shares (Form 4, code A).
- Jun 20, 2025: Open-market sale of QURE shares (Form 4, code S).
- Jun 12, 2025: Grant or award of CGEM derivative securities (Form 4, code A).
Other insiders filing for Cullinan Therapeutics, Inc. (CGEM)
- Michaelson Jennifer, Chief Scientific Officer
- SUMER JACQUELYN L, Chief Legal Officer
- Fenton Mary Kay, Chief Financial Officer
- Rosenberg Anthony, Director
- Webster Stephen W, Director
- Allen Andrew R, Director